ArticleOncotarget2018
Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.
Open access · diamondAbstract read
In one paragraph
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 51 citations in OpenAlex.
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
- Malignant adenomyoepithelioma withOncology letters · 2026Article
- Exploration of potential biomarkers in salivary duct carcinoma based on bioinformatics analysis.Scientific reports · 2026Article
- NovelCase reports in pathology · 2025Article
- Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?Head and neck pathology · 2022Article
- The Therapeutic Landscape of Salivary Gland Malignancies-Where Are We Now?International journal of molecular sciences · 2022Review
- Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling.NPJ precision oncology · 2022Article
- Expanding the clinicopathological spectrum of TGFBR3-PLAG1 rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation.Genes, chromosomes & cancer · 2022Article
- An Overview on the Histogenesis and Morphogenesis of Salivary Gland Neoplasms and Evolving Diagnostic Approaches.Cancers · 2021Review
- The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.Frontiers in oncology · 2021Article
- Genomic and Clinical Correlates of Adrenocortical Carcinoma in an Adult Patient with Li-Fraumeni Syndrome: A Case Report.Current oncology (Toronto, Ont.) · 2020Article
- Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment.Cancer cytopathology · 2020Review
- Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.Cancer immunology, immunotherapy : CII · 2020Article
- Enhanced Angiogenesis in Salivary Duct Carcinoma Ex-Pleomorphic Adenoma.Frontiers in oncology · 2020Article
- The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities.Theranostics · 2020Article
- Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.Cancer medicine · 2019Article
- Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.Frontiers in oncology · 2019Article
- Carboplatin and Docetaxel in Patients With Salivary Gland Carcinoma: A Retrospective Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 12 institutions in 1 country.
Tomotaka Shimura *Department of Otorhinolaryngology, Showa University School of Medicine, Tokyo, Japan.
Yuichiro Tada *Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Hideaki Hirai *Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Daisuke KawakitaDepartment of Otolaryngology Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Satoshi KanoDepartment of Otolaryngology Head and Neck Surgery, Hokkaido University Graduate School of Medicine, Sapporo, Japan.
Kiyoaki TsukaharaDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Akira ShimizuDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Soichiro TakaseDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Yorihisa ImanishiDepartment of Otolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki OzawaDepartment of Otolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Kenji OkamiDepartment of Otolaryngology Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Yuichiro SatoDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Yukiko SatoDepartment of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Chihiro FushimiDepartment of Otolaryngology Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hideaki TakahashiDepartment of Otolaryngology Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takuro OkadaDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Hiroki SatoDepartment of Otolaryngology Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Kuninori OtsukaDepartment of Otolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Yoshihiro WatanabeDepartment of Otolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Akihiro SakaiDepartment of Otolaryngology Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Koji EbisumotoDepartment of Otolaryngology Head and Neck Surgery, Tokai University School of Medicine, Isehara, Japan.
Takafumi TogashiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Yushi UekiDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Hisayuki OtaDepartment of Head and Neck Surgery, Niigata Cancer Center Hospital, Niigata, Japan.
Mizuo AndoDepartment of Otolaryngology Head and Neck Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Shinji KohsakaDepartment of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Toyoyuki HanazawaDepartment of Otolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Hideaki ChazonoDepartment of Otolaryngology, Head and Neck Surgery, Chiba University Graduate School of Medicine, Chiba, Japan.
Yoshiyuki KadokuraDepartment of Otorhinolaryngology, Showa University Northern Yokohama Hospital, Yokohama, Japan.
Hitome KobayashiDepartment of Otorhinolaryngology, Showa University School of Medicine, Tokyo, Japan.
Toshitaka NagaoDepartment of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
Tokyo Medical University · JPKeio University · JPNagoya City University · JPNiigata Cancer Center Hospital · JPTokai University · JPChiba University · JPJapanese Foundation For Cancer Research · JPShowa University Northern Yokohama Hospital · JPThe University of Tokyo · JPHokkaido University · JPMita Hospital · JPShowa University · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
The molecular characteristics of therapeutically-relevant targets and their clinicopathological implications in salivary duct carcinomas (SDCs) are poorly understood. We investigated the gene alterations and the immunoexpression of crucial oncogenic molecules in 151 SDCs. The mutation rates that were identified, in order of frequency, were as follows:
Indexed as
H-RASPI3K/Akt signaling pathwayPIK3CAsalivary duct carcinomaTP53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.